Revenue Breakdown
Composition ()
No data
Revenue Streams
Insmed Inc (INSM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Arikayce, accounting for 80.3% of total sales, equivalent to $114.29M. Another important revenue stream is Brinsupri. Understanding this composition is critical for investors evaluating how INSM navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Insmed Inc maintains a gross margin of 82.51%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -94.64%, while the net margin is -124.50%. These profitability ratios, combined with a Return on Equity (ROE) of -249.28%, provide a clear picture of how effectively INSM converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, INSM competes directly with industry leaders such as HLN and BIIB. With a market capitalization of $31.54B, it holds a significant position in the sector. When comparing efficiency, INSM's gross margin of 82.51% stands against HLN's 64.19% and BIIB's 72.46%. Such benchmarking helps identify whether Insmed Inc is trading at a premium or discount relative to its financial performance.
